AL2846
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.AL2846 is one of 180 small molecule programs targeting Neurofibromatosis. It is currently in Phase 3.
7
Indications
9
Total Trials
1
Active Trials
179
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1AL2846
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Yervoy
Bristol-Myers SquibbPreclinical
PORTRAZZA
Eli LillyPreclinical
Vizimpro
PfizerPreclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
REGN2810
RegeneronPreclinical
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thyroid Cancer1 trial
Neurofibromatosis1 trial
Patients With Advanced Solid Tumors1 trial
Differentiated Thyroid Carcinoma1 trial
4 more indications
Pancreatic Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AL2846. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details